Aiforia Technologies: Potential starting to weigh more than risks
Aiforia's growth strategy implementation has progressed convincingly. Considering this we believe even more in its ability to take a significant role in its target market in the next decade. The valuation clearly leans forward (23-24e EV/S 24-13x) and the risks of valuation multiples falling is still high. However, considering recent performance, we expect business growth to compensate sufficiently for this.
Aiforia Technologies
Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of areas from oncology to neuroscience. Aiforia Technologies is headquartered in Finland.
Read more on company pageKey Estimate Figures02.03.2023
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 1.9 | 4.2 | 8.6 |
growth-% | 91.79 % | 125.89 % | 103.27 % |
EBIT (adj.) | -10.2 | -11.2 | -11.5 |
EBIT-% (adj.) | -546.20 % | -264.41 % | -133.85 % |
EPS (adj.) | -0.41 | -0.44 | -0.44 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | - | - | - |